Charles Coombes, MD, PhD, Imperial College London, London, UK, highlights key learnings from this years San Antonio Breast Cancer Symposium 2021, including the findings from EMERALD (NCT03778931), a Phase III study evaluating elacestrant vs standard of care in patients with HR+/HER2- breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

свернуть